Merck Announces First-Quarter 2010 Financial Results
- Details
- Category: Merck
Merck & Co., Inc. (NYSE: MRK) announced financial results for the first quarter of 2010. Worldwide sales for the first quarter of 2010 were $11.4 billion. Net income for the first quarter was $299 million. Foreign exchange for the quarter favorably affected global sales performance by 4 percent.
FDA approved VIMOVO for arthritis patients at risk of developing NSAID-associated gastric ulcers
- Details
- Category: AstraZeneca
AstraZeneca and POZEN Inc. announced the US Food and Drug Administration (FDA) has approved VIMOVO (naproxen and esomeprazole magnesium) delayed-release tablets for the relief of signs and symptoms of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis, and to decrease the risk of developing gastric ulcers in patients at risk of developing NSAID-associated gastric ulcers.
Nycomed and Merck & Co., Inc., announce commercialization agreements for Daxas®
- Details
- Category: Nycomed
Nycomed and Merck & Co., Inc. have entered into a co-promotion agreement for Canada and certain European countries for the commercialization of Daxas® (roflumilast), an investigational once-daily tablet for patients with chronic obstructive pulmonary disease (COPD).
Bristol-Myers Squibb Reports Strong Sales, Earnings Performance in First Quarter
- Details
- Category: Bristol-Myers Squibb
Bristol-Myers Squibb Company (NYSE: BMY) reported strong sales and earnings growth for the first quarter of 2010. "Double-digit growth for both sales and earnings per share marks a very positive start to the year for our company," said Lamberto Andreotti, CEO-designate, Bristol-Myers Squibb.
AstraZeneca's first quarter results reflect continued strong market performance
- Details
- Category: AstraZeneca
AstraZeneca's revenue in the first quarter increased by 7 percent at CER, but was up 11 percent on an actual basis as a result of the positive impact of exchange rate movements.
Bayer achieves strong gains in sales and earnings
- Details
- Category: Bayer
Sales of the Bayer Group rose by 5.3 percent in the first quarter to EUR 8,316 million (Q1 2009: EUR 7,895 million). Adjusted for currency and portfolio effects, business grew by 6.2 percent.
Boehringer Ingelheim grows faster than the pharmaceutical market
- Details
- Category: Boehringer Ingelheim
Boehringer Ingelheim continued to grow in 2009, increasing its net sales by 9.7% to EUR 12.7 billion (2008: EUR 11.6 billion). This was announced by the company at its Annual Press Conference. Even without taking into account positive currency effects, growth was once again above the average growth for the worldwide pharmaceutical market, at 6.7%.
More Pharma News ...
- Despite Concern, Americans Aren't Protecting Themselves Against Diabetes
- Roche Group sustained its strong sales growth in the first three months of 2010
- Novo Nordisk's operating profit increased by 15% in the first quarter of 2010
- Novartis healthcare portfolio generates strong growth in first quarter of 2010
- World Bank and Pfizer Announce Initiative to Help Improve Healthcare Delivery
- Superior efficacy of Victoza® (liraglutide) compared to Januvia® (sitagliptin)
- Pfizer Discontinues Phase 3 Trial of Sutent® in Advanced Hepatocellular Carcinoma